Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Parker Waichman LLP Headlines by Topic

Byetta

Byetta, Januvia Cancer Risks Debated

Sep 21, 2011
| Parker Waichman LLP
The uncertainty surrounding type 2 diabetes drugs like  Byetta and Januvia have prompted calls for more studies of glucagon-like peptide 1...

Study Find Januvia, Byetta Associated with Increased Risk of Pancreatitis, Pancreatic Cancer

Sep 19, 2011
| Parker Waichman LLP
Diabetes drugs that lower blood sugar by promoting the action of a gut hormone called glucagon-like peptide 1 (GLP-1) may increase the risks of both...

Byetta, Victoza Raise More Cancer Fears

Sep 13, 2011
| Parker Waichman LLP
A new study is adding to concerns that type 2 drugs like Byetta and Victoza could increase the likelihood that a patient will develop pancreatitis...

Doctors Reminded of Victoza Thyroid Tumor, Pancreatitis Risks

Jun 14, 2011
| Parker Waichman LLP
It seems many doctors are unaware of the serious side effects that may be associated with the Type II Diabetes drug Victoza.  As a result, Novo...

Victoza Report Raises Byetta Safety Questions

Jun 7, 2011
| Parker Waichman LLP
A new report from the Institute for Safe Medicine Practices (ISMP) may raise safety concerns about a new generation of diabetes drugs, including...

Byetta Cancer Lawsuit Filed in Florida

Jun 3, 2011
| Parker Waichman LLP
A Byetta lawsuit filed in Florida last year claims the Type II Diabetes drug caused pancreatic and liver cancer.  The Byetta cancer lawsuit...

FDA Says Promotions, Statements by 4 Drug Makers are Misleading

Jan 13, 2010
| Parker Waichman LLP
Four drug makers  have received Food & Drug Administration (FDA) warning letters for misleading promotions and statements about their...

Byetta Patients Report Kidney Problems, Label Revised

Nov 3, 2009
| Parker Waichman LLP
The labeling for Byetta, a drug used to treat type 2 diabetes, has been revised to include new safety information about possible kidney function...

Another Byetta Delay

Dec 9, 2008
| Parker Waichman LLP
Federal regulators are extending a review of the diabetes drug Byetta into next year, Forbes.com is reporting.  The Food & Drug...

Flagging Byetta Sales Force Job Cuts at Amylin

Nov 12, 2008
| Parker Waichman LLP
Safety concerns surrounding the diabetes drug Byetta have slowed its sales, forcing Amylin Pharmaceuticals to cut a quarter of its work force....

Page 1/2 [first] [prev] 1 2 [next] [last]